
Opinion|Videos|December 23, 2024
Final Thoughts: The Spesolimab and GPP Flare Reduction
Key Takeaways
Panelists discuss how the Effisayil 2 trial's results suggest that spesolimab offers a promising strategy for reducing the frequency and severity of GPP flares, potentially revolutionizing the management of this severe and life-threatening condition.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5

















